<DOC>
	<DOCNO>NCT02642393</DOCNO>
	<brief_summary>A multicenter , randomize , double-blind , placebo-controlled , phase 3 trial determine whether oral inosine dose moderately elevate serum urate ( ≤5.7 mg/dL 7.1-8.0 mg/dL ) 2 year slow clinical decline early PD . Clinical decline assess change primary outcome variable Movement Disorders Society-Unified Parkinson 's Disease Rating Scale ( MDS-UPDRS ) , composite scale comprise patient- clinician-reported outcome .</brief_summary>
	<brief_title>Study Urate Elevation Parkinson 's Disease , Phase 3</brief_title>
	<detailed_description>Capsules contain 500 mg inosine ( active drug ) ~500 mg lactose ( placebo ) take orally two capsule three time per day ( i.e. , 3 g/day ) 24 month . In inosine-treated group number capsule take per day titrate serum urate level - measure trough study visit three month apart - order achieve concentration 7.1-8.0 mg/dL . Initial dosing tailor individualized factor include gender pretreatment serum urate , advance gradually toward project target dose . Adjustments dose placebo capsule control arm algorithm-based match dose inosine capsule active drug arm . Following study drug discontinuation subject follow 3-month wash-out period telephone call final study visit . All study visit screen include measurement primary outcome variable ( MDS-UPDRS ) include secondary outcome variable : adverse event , dose adjustment , disability warrant initiation dopaminergic therapy , Quality Life Neurological Disorders ( Neuro-QOL ) , 39-item Parkinson 's Disease Questionnaire ( PDQ-39 ) , Schwab &amp; England Activities Daily Living ( S &amp; E ADL ) scale , Montreal Cognitive Assessment ( MoCA ) , orthostatic vital sign .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Uric Acid</mesh_term>
	<criteria>INCLUSION CRITERIA : Study subject meeting follow criterion allow enroll study : 1 . Willingness ability give write informed consent comply trial procedure . 2 . Fulfillment diagnostic criterion idiopathic PD least two cardinal sign PD ( rest tremor , bradykinesia , rigidity ) present 2nd screen baseline evaluation , assess Site Investigator . 3 . Absence current imminent ( within 90 day enrollment ) PD disability require dopaminergic therapy , assess Site Investigator . 4 . Modified Hoehn Yahr Scale Stage 1 2.5 inclusive . 5 . Age 30 old time PD diagnosis . 6 . Diagnosis PD make within 3 year prior 1st Screening Visit . 7 . Nonfasting serum urate ≤ 5.7 mg/dL 1st Screening Visit ( SC1 ) . 8 . If subject female , : 1 . Being surgically sterile ( hysterectomy tubal ligation ) , 2 . Being postmenopausal ( last menstruation two year prior 2nd Screening Visit ) , 3 . For childbearing potential Using reliable form contraception 60 day prior Baseline Visit agree continue use 30 day post last dose study drug . Reliable form contraception include : abstinence ; implant , injected oral contraceptive ( birth control pill ) , intrauterine device place least 3 month prior Baseline Visit , vaginal ring spermicide , barrier spermicide male female condom , diaphragm cervical cap , transdermal patch ; male partner vasectomy . And negative pregnancy test 2nd Screening Visit . [ Note urine pregnancy test perform screen woman least two year postmenopausal surgically sterile . ] EXCLUSION CRITERIA : Study subject meeting follow criterion screen evaluation exclude entry study : 1 . Atypical parkinsonism , include due drug , metabolic disorder , encephalitis , cerebrovascular disease , normal pressure hydrocephalus , neurodegenerative disease . 2 . Dopamine transporter ( DAT ) brain scan without evidence dopamine deficit . 3 . History gout . 4 . History uric acid urate urolithiasis , recurrent urolithiasis unknown type . 5 . A screening test positive uric acid crystalluria , urine pH ≤ 5.0 , estimate glomerular filtration rate &lt; 60 ml/min/1.73 m2 . 6 . History myocardial infarction stroke . 7 . Symptomatic congestive heart failure document ejection fraction 45 % . 8 . History severe chronic obstructive pulmonary disease . 9 . Mini Mental State Exam score &lt; 25 ; i.e. , score 0 24 . 10 . Use antiparkinsonian medication ( include levodopa , dopamine agonist , amantadine , entacapone anticholinergic agent trihexyphenidyl benztropine ) monoamine oxidaseB inhibitor within 60 day Baseline , excess 90 day . 11 . Change dosage ( initiation ) monoamine oxidaseB ( MAOB ) inhibitor within 90 day prior Baseline , i.e. , entry MAOB inhibitor require stable dosage 90 day prior Baseline . 12 . Use follow within 30 day prior Baseline Visit : inosine , allopurinol , febuxostat , probenecid , 50 IU vitamin E daily , 300 mg vitamin C daily ( though daily standard multivitamin Bayer OneADay® Centrum® permissible ) , reserpine , methylphenidate , amphetamine , cinnarizine , monoamine oxidaseA inhibitor , tetrabenazine , neuroleptic dopamine block drug . 13 . Use follow within 90 day prior DAT neuroimaging screen evaluation : modafinil , armodafinil , metoclopramide , alphamethyldopa , methylphenidate , reserpine , amphetamine derivative . 14 . Unstable dose thiazide hydrochlorothiazide ( e.g. , Esidrex ) , chlorothiazide ( e.g. , Diuril ) , chlorthalidone ( e.g. , Hygroton ) , indapamide ( e.g. , Lozol ) , metolazone ( e.g. , Zaroxolyn ) , permissible long subject stable dose 1 week prior 1st Screening Visit Baseline Visit . 15 . Known unstable medical psychiatric condition may compromise participation study . ( Note difficulty swallow large capsule might preclude participation due size study drug capsule . ) 16 . Clinically serious abnormality screen visit laboratory study ECG , determine Site Investigator . 17 . Participation another investigational treatment study within 30 day prior Baseline Visit . 18 . Known hypersensitivity intolerability inosine . 19 . Known hypersensitivity DaTscan ( either active substance ioflupane I123 excipients ) .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>SURE-PD3</keyword>
	<keyword>Parkinson 's disease</keyword>
	<keyword>PD</keyword>
	<keyword>Inosine</keyword>
	<keyword>Urate</keyword>
	<keyword>Parkinson Study Group ( PSG )</keyword>
</DOC>